Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929015 · ClinicalTrials.gov registry record · NA
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
A NA study of Peritoneal Carcinomatosis and Liver and Intrahepatic Bile Duct Carcinoma, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT04929015 is a NA study of Peritoneal Carcinomatosis and Liver and Intrahepatic Bile Duct Carcinoma that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 30 participants, below the 58-participant average among 14 other Peritoneal Carcinomatosis trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04929015, a NA study of Peritoneal Carcinomatosis and Liver and Intrahepatic Bile Duct Carcinoma, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis. Deoxyribonucleic acid, or DNA, is the material that carries all the information about how a living thing will work and function. Everyone is born with the same DNA in all our cells throughout our body. Sometimes, some of the cells in the body develop abnormalities in the DNA that cause those cells to grow abnormally and uncontrollably. Cancer occurs when there is abnormal and uncontrolled growth of cells. The DNA in cancer cells is therefore different from the DNA someone is born with. The Signatera ctDNA assay is a laboratory test that takes tumor (cancer) tissue and evaluates it for unique tumor DNA. This evaluation is used to create a report (otherwise known as an assay) personalized to each person's cancer. The personalized assay creates a personalized blood test to detect the level of abnormal DNA from the cancer that may be circulating in the body. Once this personalized blood assay is designed, it may be used to monitor a person's blood for the presence of ctDNA, which will indicate the presence or absence of cancer over time, even after treatment.
Conditions Studied
Interventions
- OTHER Electronic Health Record Review
- PROCEDURE Biospecimen Collection - blood and tissue sample collection
Study Locations (2)
New Jersey
- RWJBarnabas Health - Cooperman Barnabas, Livingston - Livingston
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2024-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04929015
The ClinicalTrials.gov registry entry for NCT04929015 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 14 other Peritoneal Carcinomatosis trials with a reported enrollment target (48% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Peritoneal Carcinomatosis appearing as the primary indexed condition, and to 2 interventions - of which Electronic Health Record Review is the first listed.
NCT04929015 reports 2 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT04929015 about?
NCT04929015 is a clinical study titled "Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)". This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis. Deoxyribonucleic acid, or DNA, is the material that carries all the information about how a living thing will work and fun...
What is the current status of trial NCT04929015?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-04-29. Estimated completion is 2024-11-01.
What conditions does trial NCT04929015 study?
This clinical trial studies the following conditions: Peritoneal Carcinomatosis, Liver and Intrahepatic Bile Duct Carcinoma, Digestive System Neoplasm, Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage.
What interventions are being tested in trial NCT04929015?
The interventions under investigation include: Electronic Health Record Review (OTHER), Biospecimen Collection - blood and tissue sample collection (PROCEDURE).
Who is sponsoring clinical trial NCT04929015?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04929015 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Carcinomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
RECRUITING · NA
-
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
RECRUITING · Phase 1
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
RECRUITING · Phase 2
-
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Peritoneal Carcinomatosis
All registered trials for this condition
Liver and Intrahepatic Bile Duct Carcinoma
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.